Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection

[1]  Yingnan Cao,et al.  Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses , 2007, Vaccine.

[2]  S. Tapscott,et al.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. , 2006, Human gene therapy.

[3]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[4]  F. Zhou,et al.  Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. , 2006, Cellular & molecular immunology.

[5]  P. Martín-Duque,et al.  Viral gene therapy , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[6]  Ma Chunling,et al.  Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice , 2006, Intervirology.

[7]  K. Yuen,et al.  Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines , 2006, Virology.

[8]  Shibo Jiang,et al.  Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.

[9]  O. Danos,et al.  Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.

[10]  J. Kleinschmidt,et al.  Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1 , 2006, Journal of Virology.

[11]  W. Mak,et al.  Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection , 2005, Nature Genetics.

[12]  Gary J. Nabel,et al.  Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization , 2005, Journal of Virology.

[13]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[14]  Shibo Jiang,et al.  Vaccine design for severe acute respiratory syndrome coronavirus. , 2005, Viral immunology.

[15]  Alan D. Roberts,et al.  Differential contributions of central and effector memory T cells to recall responses , 2005, The Journal of experimental medicine.

[16]  P. Woo,et al.  SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus , 2005, Vaccine.

[17]  L. Babiuk,et al.  Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines , 2005, Vaccine.

[18]  Shibo Jiang,et al.  Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies , 2005, The Journal of Immunology.

[19]  W. Hong,et al.  Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents , 2005, Journal of Virology.

[20]  Hao Shen,et al.  Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein , 2005, Virology.

[21]  Shibo Jiang,et al.  SARS vaccine development. , 2005, Emerging infectious diseases.

[22]  R. Proulx,et al.  Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.

[23]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[24]  B. Murphy,et al.  Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Murphy,et al.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.

[26]  D. Normile.  Mounting Lab Accidents Raise SARS Fears , 2004, Science.

[27]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[28]  Y. Guan,et al.  SARS-related Virus Predating SARS Outbreak, Hong Kong , 2004, Emerging infectious diseases.

[29]  C. Orellana.  Laboratory-acquired SARS raises worries on biosafety , 2004, The Lancet Infectious Diseases.

[30]  Y. Guan,et al.  Prophylactic and Therapeutic Effects of Small Interfering Rna Targeting Sars-Coronavirus , 2003, Antiviral therapy.

[31]  D. Normile.  Infectious diseases. Mounting lab accidents raise SARS fears. , 2004, Science.

[32]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[33]  D. Normile.  SARS Experts Want Labs to Improve Safety Practices , 2003, Science.

[34]  H. Mizukami,et al.  Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. , 2002, Human gene therapy.